Karen Liu

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Alavita Pharmaceuticals, Inc. develops pharmaceutical therapeutic products. The company was founded on October 9, 2007 and is headquartered in Los Altos, CA.

Part of Insightful Science Holdings LLC, Protein Metrics, Inc. is a company that specializes in protein characterization. The company is based in Cupertino, CA at the crossroads of computing and biotechnology. The company's vendor-neutral software enables scientists to quickly identify and report protein sequences and variations from the expected form using data generated on analytical instruments like mass spectrometers. The company was founded by Yong Kil, Marshall Bern, Chris Becker, and Eric Carlson has been the CEO of the company since 2014. Protein Metrics was acquired by Insightful Science Holdings LLC on December 21, 2021.

Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001.

Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom.

SurroMed, Inc. provides pharmaceutical research. It focuses on discovering & applying biomarkers to improve the drug discovery and development process and enable the precise diagnosis and personalized treatment of disease. The company's research process yields biological markers and information that enable accelerated, cost-efficient discovery and development of new therapeutic products, as well as development of diagnostic tests for early disease detection, disease staging, patient stratification, guiding and monitoring therapy. SurroMed was founded in 1997 and is located in Menlo Park, CA.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Maverix Biomics, Inc. provides cloud-based platform to manage, analyze and visualize genomic data. It also builds communities of discovery and place its data in context with the latest public data from the full spectrum of life, including human, plant, animal or microbial organisms. The company was founded by David Mandelkern, Todd Michael Johnson Lowe and Patricia Pak Lee Chan in 2010 and is headquartered in San Mateo, CA.

Okava Pharmaceuticals, Inc. is an American clinical stage biotechnology company.

Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016.

Rapafusyn Research & Development, Inc. develops non-degrading molecular glues. The company is based in Baltimore, MD. The CEO of the company is Sean X. Hu.